110 related articles for article (PubMed ID: 20921890)
1. An open-label tolerability study of BL-1020 antipsychotic: a novel gamma aminobutyric acid ester of perphenazine.
Anand R; Geffen Y; Vasile D; Dan I
Clin Neuropharmacol; 2010; 33(6):297-302. PubMed ID: 20921890
[TBL] [Abstract][Full Text] [Related]
2. BL-1020, an oral antipsychotic agent that reduces dopamine activity and enhances GABAA activity, for the treatment of schizophrenia.
Fitzgerald PB
Curr Opin Investig Drugs; 2010 Jan; 11(1):92-100. PubMed ID: 20047163
[TBL] [Abstract][Full Text] [Related]
3. Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.
Geffen Y; Keefe R; Rabinowitz J; Anand R; Davidson M
J Clin Psychiatry; 2012 Sep; 73(9):e1168-74. PubMed ID: 23059159
[TBL] [Abstract][Full Text] [Related]
4. BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia.
Geffen Y; Nudelman A; Gil-Ad I; Rephaeli A; Huang M; Savitsky K; Klapper L; Winkler I; Meltzer HY; Weizman A
Eur Neuropsychopharmacol; 2009 Jan; 19(1):1-13. PubMed ID: 18757185
[TBL] [Abstract][Full Text] [Related]
5. A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects.
Nudelman A; Gil-Ad I; Shpaisman N; Terasenko I; Ron H; Savitsky K; Geffen Y; Weizman A; Rephaeli A
J Med Chem; 2008 May; 51(9):2858-62. PubMed ID: 18363346
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
7. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
8. BL-1020, a novel antipsychotic candidate with GABA-enhancing effects: D2 receptor occupancy study in humans.
Appel L; Geffen Y; Heurling K; Eriksson C; Antoni G; Kapur S
Eur Neuropsychopharmacol; 2009 Dec; 19(12):841-50. PubMed ID: 19717284
[TBL] [Abstract][Full Text] [Related]
9. Long-term depot neuroleptic treatment with perphenazine decanoate. II. Different depot intervals in the last 6 months of a 12 month study of 42 drug monitored psychotic patients.
Knudsen P; Hansen LB; Højholdt K; Larsen NE
Acta Psychiatr Scand Suppl; 1985; 322():41-50. PubMed ID: 3934921
[TBL] [Abstract][Full Text] [Related]
10. Stability of medication in early psychosis: a comparison between second-generation and low-dose first-generation antipsychotics.
Opjordsmoen S; Melle I; Friis S; Haahr U; Johannessen JO; Larsen TK; Rund BR; Simonsen E; Vaglum P; McGlashan TH
Early Interv Psychiatry; 2009 Feb; 3(1):58-65. PubMed ID: 21352176
[TBL] [Abstract][Full Text] [Related]
11. Long-term depot neuroleptic treatment with perphenazine decanoate. I. Efficacy and side effects in a 12 month study of 42 drug monitored psychotic patients.
Knudsen P; Hansen LB; Højholdt K; Larsen NE
Acta Psychiatr Scand Suppl; 1985; 322():29-40. PubMed ID: 3907279
[TBL] [Abstract][Full Text] [Related]
12. Controlled cross-over comparison of isofloxythepin and perphenazine in the treatment of schizophrenic psychoses.
Svestka J; Náhunek K; Cesková E; Rysánek R; Balsíková J
Act Nerv Super (Praha); 1989 Apr; 31(1):32-4. PubMed ID: 2571218
[No Abstract] [Full Text] [Related]
13. Perphenazine decanoate vs. perphenazine enanthate: efficacy and side effects in a 6 week double-blind, comparative study of 50 drug monitored psychotic patients.
Knudsen P; Hansen LB; Auken G; Waehrens J; Højholdt K; Larsen NE
Acta Psychiatr Scand Suppl; 1985; 322():15-28. PubMed ID: 3907278
[TBL] [Abstract][Full Text] [Related]
14. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
15. Amoxapine as an antipsychotic: comparative study versus haloperidol.
Chaudhry IB; Husain N; Khan S; Badshah S; Deakin B; Kapur S
J Clin Psychopharmacol; 2007 Dec; 27(6):575-81. PubMed ID: 18004123
[TBL] [Abstract][Full Text] [Related]
16. Open trial study of a combined antidepressant (amitryptiline, perphenazine, diazepam) versus fluoxetine or imipramine in ambulatory depressed patients.
Diaz A; Fouilloux C; Ortiz S
Proc West Pharmacol Soc; 2002; 45():154-5. PubMed ID: 12434564
[No Abstract] [Full Text] [Related]
17. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder.
Elie D; Poirier M; Chianetta J; Durand M; Grégoire C; Grignon S
J Psychopharmacol; 2010 Jul; 24(7):1037-44. PubMed ID: 19164494
[TBL] [Abstract][Full Text] [Related]
18. Drugs in development for the treatment of schizophrenia.
Emsley R
Expert Opin Investig Drugs; 2009 Aug; 18(8):1103-18. PubMed ID: 19589093
[TBL] [Abstract][Full Text] [Related]
19. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
Bret P; Bret MC; Queuille E
Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
[TBL] [Abstract][Full Text] [Related]
20. Adding other antipsychotics to clozapine.
Cooke C; de Leon J
J Clin Psychiatry; 1999 Oct; 60(10):710. PubMed ID: 10549694
[No Abstract] [Full Text] [Related]
[Next] [New Search]
